Dicerna Pharmaceuticals Inc (DRNA) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
78 |
Employees |
190 |
Revenues (TTM) (Millions $) |
193 |
Net Income (TTM) (Millions $) |
-124 |
Cash Flow (TTM) (Millions $) |
-39 |
Capital Exp. (TTM) (Millions $) |
12 |
Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi) therapeutics for the treatment of various diseases. The company is based in Lexington, Massachusetts and was founded in 2007, by a team of RNAi experts including Dr. James E. J. Bedard, Dr. Douglas M. Fambrough, and Dr. Dale L. Ludwig.
RNA interference is a natural process that cells use to silence or turn off the expression of a specific gene. Dicerna Pharmaceuticals is focused on using this process to target and treat a range of genetic diseases including cancer, liver diseases, viral infections, and rare genetic disorders.
The company has developed a proprietary platform called the Dicer substrate technology (DST) which enables the design and delivery of highly specific RNAi therapies. The DST platform focuses on enhancing the stability and specificity of RNAi molecules, which facilitates the development of RNAi therapies with improved therapeutic potential.
Dicerna Pharmaceuticals is currently in the process of developing multiple RNAi therapeutics, including its lead product candidate, DCR-PHXC, a treatment for primary hyperoxaluria (PH). PH is a rare, inherited metabolic disease that causes the buildup of oxalate in the kidneys, leading to kidney damage and failure. Dicerna Pharmaceuticals is also developing RNAi therapeutics for the treatment of other liver diseases, including hepatitis B and nonalcoholic steatohepatitis (NASH).
The company has a strategic partnership with Roche to develop RNAi therapeutics for the treatment of hepatitis B, and with Eli Lilly to develop RNAi therapeutics for the treatment of cardiovascular disease.
Dicerna Pharmaceuticals has also been recognized for its work in the RNAi field, receiving grants from organizations such as the National Institutes of Health (NIH), the Massachusetts Life Sciences Center (MLSC), and the Bill & Melinda Gates Foundation.
In summary, Dicerna Pharmaceuticals Inc is a clinical-stage company focused on using RNAi therapeutics to treat a range of genetic diseases. Its proprietary DST platform enables the design and delivery of highly specific RNAi therapies, and the company is currently developing multiple RNAi therapeutics for the treatment of various liver diseases and rare genetic disorders.
Company Address: 75 Hayden Avenue Lexington 2421 MA
Company Phone Number: 621-8097 Stock Exchange / Ticker: NASDAQ DRNA
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
-1.63 $ |
Revenues (TTM) |
2.48 $
|
Cash Flow (TTM) |
- |
Cash |
2.13 $
|
Book Value |
1.38 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-1.63 $
|
Revenues (TTM) |
2.48 $ |
Cash Flow (TTM) |
- |
Cash |
2.13 $
|
Book Value |
1.38 $ |
Dividend (TTM) |
0 $ |
|
|
|
|